Imaging Glycosylation In Vivo by Metabolic Labeling and Magnetic Resonance Imaging.
André A NevesYéléna A WainmanAlan WrightMikko I KettunenTiago B RodriguesSarah McGuireDe-En HuFlaviu BulatSimonetta Geninatti CrichHenning StöckmannFinian J LeeperKevin M BrindlePublished in: Angewandte Chemie (Weinheim an der Bergstrasse, Germany) (2015)
Glycosylation is a ubiquitous post-translational modification, present in over 50 % of the proteins in the human genome,1 with important roles in cell-cell communication and migration. Interest in glycome profiling has increased with the realization that glycans can be used as biomarkers of many diseases,2 including cancer.3 We report here the first tomographic imaging of glycosylated tissues in live mice by using metabolic labeling and a gadolinium-based bioorthogonal MRI probe. Significant N-azidoacetylgalactosamine dependent T1 contrast was observed in vivo two hours after probe administration. Tumor, kidney, and liver showed significant contrast, and several other tissues, including the pancreas, spleen, heart, and intestines, showed a very high contrast (>10-fold). This approach has the potential to enable the rapid and non-invasive magnetic resonance imaging of glycosylated tissues in vivo in preclinical models of disease.
Keyphrases
- contrast enhanced
- magnetic resonance imaging
- single cell
- magnetic resonance
- cell therapy
- gene expression
- computed tomography
- high resolution
- diffusion weighted imaging
- endothelial cells
- living cells
- quantum dots
- papillary thyroid
- stem cells
- dna methylation
- metabolic syndrome
- mesenchymal stem cells
- young adults
- risk assessment
- fluorescent probe